Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype
- 7 August 2012
- journal article
- Published by Wiley in Histopathology
- Vol. 62 (3) , 472-480
Abstract
Aims: To study the clinicopathological and prognostic value of cyclin D1 overexpression in patients with breast carcinoma.Methods and results: Immunohistochemistry was performed on paraffin‐embedded tissue specimens from 290 invasive breast carcinomas to detect the proteins cyclin D1, oestrogen receptor (ER), progesterone receptor (PR), p53, c‐erbB2, and topoisomerase IIα (topoIIα). Cyclin D1 staining was quantified using a computerized image analysis method. Cyclin D1 overexpression characterized smaller, ER‐positive and PR‐positive tumours (P = 0.017, P < 0.0001, and P < 0.0001, respectively), of a lower histological and nuclear grade (P = 0.011 and P < 0.0001, respectively), and with reduced expression of topoIIα (P = 0.001) and p53 (P < 0.001). Cyclin D1 was found to have an independent favourable impact on the overall survival of both the unselected cohort of patients (P = 0.011) and of patients with ER‐negative and lymph node‐positive tumours (P = 0.034 and P = 0.015, respectively). In triple‐negative tumours, cyclin D1 overexpression was found to have independent favourable impacts on both overall and relapse‐free survival (P = 0.002 for both).Conclusions: This is the first immunohistochemical study to dissociate the advantageous prognostic effect of cyclin D1 overexpression from its association with ER expression, and to provide evidence that cyclin D1 overexpression may be a marker of prolonged survival in patient subgroups with aggressive phenotypes.Keywords
This publication has 33 references indexed in Scilit:
- Molecular classification of breast cancer: is it time to pack up our microscopes?Pathology, 2011
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosisLaboratory Investigation, 2010
- High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancerInternational Journal of Cancer, 2009
- Nuclear cyclin D1: An oncogenic driver in human cancerJournal of Cellular Physiology, 2009
- Abrogated Response to Cellular Stress Identifies DCIS Associated with Subsequent Tumor Events and Defines Basal-like Breast TumorsCancer Cell, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patientsPathology International, 2003
- DNA Topoisomerase II-Alpha Immunoreactivity as a Marker of Tumor Aggressiveness in Invasive Breast CancerPathobiology, 2000